Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders

Rhea-AI Summary

Pharming Group announced the results of its 2024 Annual General Meeting (AGM) held on May 21, 2024. All proposals were approved by shareholders, including the reappointment of Ms. Barbara Yanni and Mr. Mark Pykett as Non-Executive Directors for four years. The updated Remuneration Policy for the Board was also accepted. Additionally, shareholders authorized the Board to issue shares and/or options and to repurchase shares. Detailed information and a recording of the AGM are available on Pharming's Investor Relations webpage.

Positive

• All proposals, including important authorizations and reappointments, were approved unanimously by shareholders.
• The reappointment of experienced Non-Executive Directors, Ms. Barbara Yanni and Mr. Mark Pykett, ensures continuity in leadership.
• The updated Remuneration Policy for the Board of Directors was accepted, potentially enhancing governance and performance.
• Shareholders authorized the Board to issue shares and/or options, providing flexibility for future capital raising activities.
• The authorization to repurchase shares can help manage share prices and return value to shareholders.

Negative

• No specific financial or operational performance data was disclosed, providing insight into the company's current state.
• The PR lacks detailed future plans or strategies despite gaining significant authorizations, leaving investor expectations unaddressed.

Leiden, the Netherlands, May 21, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM/Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM) held today, all proposals were approved.
The shareholders approved the proposals to reappoint Ms. Barbara Yanni (agenda item 4.a) and Mr. Mark Pykett (agenda item 4.b), upon binding recommendation of the Board of Directors, as Non-Executive Directors for a period of four years.

In addition, the proposals for the adoption of the updated Remuneration Policy for members of the Board of Directors (agenda item 3), the authorization for the Board of Directors to issue shares and/or options (agenda item 5) and the authorization for the Board of Directors to repurchase shares (agenda item 6) were approved by the shareholders.

A recording of the webcast, presentation slides from today’s AGM, and more details regarding agenda items are available on the Company’s website in the Investor Relations section.

About Pharming Group N.V.

Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics that are in clinical development. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.

For more information, visit www.pharming.com and find us on LinkedIn.

Inside Information

This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

For further public information, contact:

Pharming Group, Leiden, The Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E: investor@pharming.com

FTI Consulting, London, UK
Victoria Foster Mitchell/Alex Shaw/Amy Byrne
T: +44 203 727 1000

LifeSpring Life Sciences Communication, Amsterdam, The Netherlands
Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl

 

FAQ

What were the results of Pharming's 2024 AGM?

All proposals were approved, including reappointments, updated remuneration policies, and authorizations for share issuance and repurchases.

Who were reappointed as Non-Executive Directors at Pharming's 2024 AGM?

Ms. Barbara Yanni and Mr. Mark Pykett were reappointed for a period of four years.

What authorizations did Pharming's Board receive at the 2024 AGM?

The Board was authorized to issue shares and/or options and to repurchase shares.

When was Pharming's 2024 Annual General Meeting held?

The AGM was held on May 21, 2024.

Where can I find more details about Pharming's 2024 AGM?

Detailed information, including presentation slides and a recording of the webcast, is available on Pharming's Investor Relations webpage.